{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:00:45Z","timestamp":1789585245478,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>X-linked hypophosphatemia (XLH) is a rare inherited phosphate-wasting disorder associated with bone and dental complications. Health-related quality of life (HRQoL) is reduced in XLH patients on conventional treatment with phosphate supplements and active vitamin D, while information on patients treated with burosumab is rare.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HRQoL was assessed in 63 pediatric XLH patients participating in a prospective, observational study and patient registry in Germany using the KIDSCREEN-52 survey instrument and standardized qualitative interviews.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median age of the XLH patients was 13.2 years (interquartile range 10.6 \u2013 14.6). At the time of the survey, 55 (87%) patients received burosumab and 8 (13%) conventional treatment. Forty-six patients (84%) currently being treated with burosumab previously received conventional treatment. Overall, HRQoL was average compared to German reference values (mean \u00b1 SD: self-report, 53.36 \u00b1 6.47; caregivers\u2019 proxy, 51.33 \u00b1 7.15) and even slightly above average in some dimensions, including physical, mental, and social well-being. In general, XLH patients rated their own HRQoL higher than their caregivers. In qualitative interviews, patients and caregivers reported that, compared with conventional therapy, treatment with burosumab reduced stress, bone pain, and fatigue, improved physical health, and increased social acceptance by peers and the school environment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this real-world study in pediatric XLH patients, HRQoL was average or even slightly above that of the general population, likely due to the fact that the vast majority of patients had their treatment modality switched from conventional treatment to burosumab resulting in improved physical health and well-being.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00467-024-06427-0","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T23:01:58Z","timestamp":1719270118000},"page":"3221-3231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Health-related quality of life of children with X-linked hypophosphatemia in Germany"],"prefix":"10.1007","volume":"39","author":[{"given":"Martin","family":"Klein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Obermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Mutze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Maria","family":"Wilden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9534-4102","authenticated-orcid":false,"given":"Mirko","family":"Rehberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Peter","family":"Schlingmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Metzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-5192","authenticated-orcid":false,"given":"Angela","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Richter-Unruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus J.","family":"Kemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-5646","authenticated-orcid":false,"given":"Marcus","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1205-2620","authenticated-orcid":false,"given":"Elke","family":"W\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Jorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Patzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Freiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Ziviknjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-7790","authenticated-orcid":false,"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9601-7813","authenticated-orcid":false,"given":"Dieter","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the German Society for Pediatric Nephrology (GPN) and the German Society for Pediatric and Adolescent Endocrinology and Diabetology (DGPAED)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"6427_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A Clinician\u2019s guide to X-linked hyperphosphatemia. J Bone Miner Res 26:1381\u20131388. https:\/\/doi.org\/10.1002\/jbmr.340","journal-title":"J Bone Miner Res"},{"key":"6427_CR2","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00467-021-05328-w","volume":"37","author":"D Haffner","year":"2022","unstructured":"Haffner D, Leifheit-Nestler M, Grund A, Schnabel D (2022) Rickets guidance: part I \u2013 diagnostic workup. Pediatr Nephrol 37:2013\u20132036. https:\/\/doi.org\/10.1007\/s00467-021-05328-w","journal-title":"Pediatr Nephrol"},{"key":"6427_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","volume":"14","author":"SS Beck-Nielsen","year":"2019","unstructured":"Beck-Nielsen SS, Mughal Z, Haffner D, Nilsson O, Levtchenko E, Ariceta G et al (2019) FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis 14:58. https:\/\/doi.org\/10.1186\/s13023-019-1014-8","journal-title":"Orphanet J Rare Dis"},{"key":"6427_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnaben D et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphatemia. Nat Rev Nephrol 15:435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"6427_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13023-022-02250-8","volume":"17","author":"R Jandhyala","year":"2022","unstructured":"Jandhyala R (2022) Concordance between the schedule for the evaluation of individual quality of life-direct weighting (SEIQoL-DW) and the EuroQoL-5D (EQ-5D) measures of quality-of-life outcomes in adults with X-linked hypophosphatemia. Orphanet J Rare Dis 17:81. https:\/\/doi.org\/10.1186\/s13023-022-02250-8","journal-title":"Orphanet J Rare Dis"},{"key":"6427_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13023-016-0538-4","volume":"11","author":"L Forestier-Zhang","year":"2016","unstructured":"Forestier-Zhang L, Watts L, Turner A, Teare H, Kaye J, Barrett J, Cooper C et al (2016) Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet J Rare Dis 11:160. https:\/\/doi.org\/10.1186\/s13023-016-0538-4","journal-title":"Orphanet J Rare Dis"},{"key":"6427_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13023-022-02452-0","volume":"17","author":"MIL Yanes","year":"2022","unstructured":"Yanes MIL, Diaz-Curiel M, Peris P, Vicente C, Marin S, Ramon-Krauel M et al (2022) Health-related quality of life of X-linked hypophosphatemia in Spain. Orphanet J Rare Dis 17:298. https:\/\/doi.org\/10.1186\/s13023-022-02452-0","journal-title":"Orphanet J Rare Dis"},{"key":"6427_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00198-020-05548-0","volume":"32","author":"L Seefried","year":"2021","unstructured":"Seefried L, Smyth M, Keen R, Harvengt P (2021) Burden of disease associated with X-linked hypophosphatemia in adults: a systemic literature review. Osteoporos Int 32:7\u201322. https:\/\/doi.org\/10.1007\/s00198-020-05548-0","journal-title":"Osteoporos Int"},{"key":"6427_CR9","doi-asserted-by":"publisher","first-page":"bvab070","DOI":"10.1210\/jendso\/bvab070","volume":"5","author":"M Cheung","year":"2021","unstructured":"Cheung M, Rylands AJ, Williams A, Bailey K, Bubbear J (2021) Patient-reported complications, symptoms, and experiences of living with X-linked hypophosphatemia across the life-course. J Endocr Soc 5:bvab070. https:\/\/doi.org\/10.1210\/jendso\/bvab070","journal-title":"J Endocr Soc"},{"key":"6427_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13023-023-02620-w","volume":"18","author":"S Cole","year":"2023","unstructured":"Cole S, Sanchez-Santos MT, Kolovos S, Javaid MK, Pinedo-Villanueva R (2023) Patient-reported outcomes measures of X-linked hypophosphatemia participants: findings from a prospective cohort study in the UK. Orphanet J Rare Dis 18:26. https:\/\/doi.org\/10.1186\/s13023-023-02620-w","journal-title":"Orphanet J Rare Dis"},{"key":"6427_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.kint.2018.08.022","volume":"94","author":"F Emma","year":"2018","unstructured":"Emma F, Haffner D (2018) FGF23 blockade coming to clinical practice. Kidney Int 94:846\u2013848. https:\/\/doi.org\/10.1016\/j.kint.2018.08.022","journal-title":"Kidney Int"},{"key":"6427_CR12","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward LM, Glorieux FH, Whyte MP, Munns CF, Portale AA, H\u00f6gler W et al (2022) Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J Clin Endocrinol Metab 107:e3241\u2013e3253. https:\/\/doi.org\/10.1210\/clinem\/dgac296","journal-title":"J Clin Endocrinol Metab"},{"key":"6427_CR13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","volume":"108","author":"R Padidela","year":"2021","unstructured":"Padidela R, Whyte MP, Glorieux FH, Munns CF, Ward LM, Nilsson O et al (2021) Patients-reported outcomes from a randomized, active-controlled, open-label, Phase 3 trial of burosumab versus conventional therapy in children with X-linked hypophosphatemia. Calcif Tissue Int 108:622\u2013633. https:\/\/doi.org\/10.1007\/s00223-020-00797-x","journal-title":"Calcif Tissue Int"},{"key":"6427_CR14","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","volume":"108","author":"A Ewert","year":"2023","unstructured":"Ewert A, Rehberg M, Schlingmann KP, Hiort O, John-Kroegel U, Metzing O et al (2023) Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia. J Endocrinol Metab 108:e998\u2013e1006. https:\/\/doi.org\/10.1210\/clinem\/dgad223","journal-title":"J Endocrinol Metab"},{"key":"6427_CR15","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00103-007-0285-8","volume":"50","author":"T Ewert","year":"2007","unstructured":"Ewert T, Stucki G (2007) Die Internationale Klassifikation der Funktionsf\u00e4higkeit, Behinderung und Gesundheit (ICF). [The International Classification of Functioning, Disability and Health (ICF)]. Bundesgesundheitsbl 50:953\u2013961. https:\/\/doi.org\/10.1007\/s00103-007-0285-8","journal-title":"Bundesgesundheitsbl"},{"key":"6427_CR16","volume-title":"Einf\u00fchrung in die ICF. Grundkurs, \u00dcbungen, offene Fragen. Introduction to the ICF. Basic course, exercises, open questions","author":"MF Schuntermann","year":"2022","unstructured":"Schuntermann MF (2022) Einf\u00fchrung in die ICF. Grundkurs, \u00dcbungen, offene Fragen. Introduction to the ICF. Basic course, exercises, open questions, 6th edn. ecomed Medizin Verlag, Heidelberg","edition":"6"},{"key":"6427_CR17","volume-title":"The Kidscreen Questionnaires \u2013 quality of life questionnaires for children and adolescents. Handbook","author":"Ravens-Sieberer U for the Kidscreen Group Europe","year":"2006","unstructured":"Ravens-Sieberer U for the Kidscreen Group Europe (2006) The Kidscreen Questionnaires \u2013 quality of life questionnaires for children and adolescents. Handbook. Pabst Science Publishers, Lengerich https:\/\/d-nb.info\/981710298"},{"key":"6427_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1026\/0012-1924\/a000257","volume":"67","author":"C Barkmann","year":"2021","unstructured":"Barkmann C, Otto C, Meyrose AK, Reiss F, W\u00fcstner A, Vo\u00df C et al (2021) Psychometrics and norms of the quality-of-life inventory KIDSCREEN in Germany. Diagnostica 67:2\u201312. https:\/\/doi.org\/10.1026\/0012-1924\/a000257","journal-title":"Diagnostica"},{"key":"6427_CR19","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00787-020-01630-4","volume":"30","author":"C Otto","year":"2020","unstructured":"Otto C, Reiss F, Voss C, W\u00fcstner A, Meyrose AK, H\u00f6lling H et al (2020) Mental health and well-being from childhood to adulthood: design, methods and results of the 11-year follow-up of the BELLA study. Eur Child Adolesc Psychiatry 30:1559\u20131577. https:\/\/doi.org\/10.1007\/s00787-020-01630-4","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"6427_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s11136-019-02189-7","volume":"28","author":"N Silva","year":"2019","unstructured":"Silva N, Pereira M, Otto C, Ravens-Sieberer U, Canavarro MC, Bullinger M (2019) Do 8- to 18-year-old children\/adolescents with chronic physical health conditions have worse health-related quality of life than their healthy peers? A meta-analysis of studies using the KIDSCREEN questionnaires. Qual Life Res 28:1725\u20131750. https:\/\/doi.org\/10.1007\/s11136-019-02189-7","journal-title":"Qual Life Res"},{"key":"6427_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12955-023-02088-z","volume":"21","author":"EG Befus","year":"2023","unstructured":"Befus EG, Helseth S, M\u00f8lland E, Westergren T, Fegran L, Haraldstad K (2023) Use of KIDSCREEN health-related quality of life instruments in the general population of children and adolescents: a scoping review. Health Qual Life Outcomes 21:6\u201316. https:\/\/doi.org\/10.1186\/s12955-023-02088-z","journal-title":"Health Qual Life Outcomes"},{"key":"6427_CR22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00467-011-1958-y","volume":"26","author":"E Elenberg","year":"2011","unstructured":"Elenberg E (2011) Quality of life in cystinosis patients. Pediatr Nephrol 26:1658\u20131659. https:\/\/doi.org\/10.1007\/s00467-011-1958-y","journal-title":"Pediatr Nephrol"},{"key":"6427_CR23","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1524-4733.2009.00508.x","volume":"12","author":"M Erhart","year":"2009","unstructured":"Erhart M, Ravens-Sieberer U, Dickinson HO, Colver A, European SPARCLE and KIDSCREEN Groups (2009) Rasch measurement properties of the KIDSCREEN quality of life instrument in children with cerebral palsy and differential item functioning between children with and without cerebral palsy. Value Health 12:782\u2013792. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00508.x","journal-title":"Value Health"},{"key":"6427_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.25009\/pys.v33i1.2774","volume":"33","author":"S Vinaccia","year":"2023","unstructured":"Vinaccia S, Barrera L, S\u00e1nchez M, Zuluaga MA, Arjona M, Franco S et al (2023) Quality of life in children with attention deficit hyperactivity disorder: from the KIDSCREEN-52. Psicol Salud 33:81\u201388. https:\/\/doi.org\/10.25009\/pys.v33i1.2774","journal-title":"Psicol Salud"},{"key":"6427_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/hae.13945","volume":"26","author":"Y Furuichi","year":"2020","unstructured":"Furuichi Y, Nogami K, Yada K, Nezu S, Obayashi K, Saeki K et al (2020) Assessment of self-\/parent-reported quality of life in Japanese children with haemophilia using the Japanese version of KIDSCREEN-52. Haemophilia 26:243\u2013250. https:\/\/doi.org\/10.1111\/hae.13945","journal-title":"Haemophilia"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06427-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:26:48Z","timestamp":1726745208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6427"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06427-0","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DH, OH, MK and DS received speaker fees, consultation fees, and research grants from Kyowa Kirin. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}